Ingested interferon alpha induces Mx mRNA

Cytokine

Volumn 11, Issue 7, 1999, Pages 492-499

  Brod, Staley A ^a   Nelson, Laura ^a   Jin, Rui ^a   Wolinsky, Jerry S ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Immunoactive protein; Interferon alpha; Mice; Mx; Oral administration

Indexed keywords

ALPHA INTERFERON; CD8 ANTIGEN; MESSENGER RNA; RECOMBINANT ALPHA2A INTERFERON; SIGNAL PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; MONONUCLEAR CELL; MOUSE; NONHUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPLEEN CELL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE;

ANIMALIA; MURINAE;

EID: 0033019248     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.1998.0450     Document Type: Article

References (49)

1. Isaacs A, Lindenmann J. Virus Interference I. The inteferon. Proc R Soc Lond (Biol). 147:1957;258-267.
2. Dron M, Tovey MG. Interferon α/β, gene structure and regulation. Baron S, Coppenhaver D, Dianzani F, Fleischmann W, Hughes T, Klimpel G, Niesel D, Stanton G, Tyring SK. Interferon - Principles and Medical Applications. 1992;33-46 UTMB Press, Galveston.
3. Uze G, Lutfalla G, Knudson KE. α and β Interferons and their receptor and their friends and relations. J Interferon Cyt Res. 15:1995;3-26.
4. Balkwill FR. The regulatory role of interferons in the human immune response. Taylor-Papadimitriou J. Interferons: Their impact in biology of medicine. 1985;61-80 Oxford Medical Publications, Oxford.
5. Neurology. 43:1993;662-667.
6. Durelli L, Bongioanni MR, Cavallo R, Ferraro B, Ferri R, Ferrio MF, Bradac GB, Riva A, Vai S, Geuna M, Bergnami L, Bergamasco B. Chronic system high-dose recombinant interferon alpha-2a reduces exacerbation rate, MRI signs of activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology. 44:1994;406-413.
7. Jacobs L, Cookfair D, Rudick R, Herndon R, Richert J, Salazar A, Fischer J, Granger C, Simon J, Goodkin D, Granger C, Simon J, Alam J, Bartoszak D, Bourdette D, Braiman J, Brownscheidle C, Coats M, Cohan S, Dougherty D, Kinkel R, Mass M, Munschauer F, Priore R, Pullicino P, Scherokman B, Whitham R, MC Group. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 39:1994;285-294.
8. Neurology. 45:1995;1277-1285.
9. 1btreatment of relapsing-remitting multiple sclerosis decreases CD3-mediated TNF-α and increases CD3-mediated IL-6 production in vitro. Neurology. 46:1996;1633-1638.
10. Brod SA, Burns DH. Suppression of relapsing experimental allergic encephalomyelitis in the SJL/J mouse by oral administration of type I interferons. Neurology. 44:1994;1144-1148.
11. Brod SA, Khan M, Pappolla M. Oral administration of human or murine IFN-α suppresses relapses and modifies adoptive transfer in experimental autoimmune encephalomyelitis. J Neuroimmunol. 58:1995;61-69.
12. Brod S, Khan M. Oral administration of murine IFN-α is more effective than parenteral administration in the suppression of relapses in EAE. J Autoimmunity. 9:1996;11-20.
13. Brod S, Darcan S, Malone M, Pappolla M, Nelson L. Ingested IFN-α suppresses IDDM in the NOD mouse. Diabetologia. 41:1997;1227-1232.
14. ser. J Interferon Res. 12:1992;411-413.
15. Horisberger MA. Mx protein: Function and mechanism of action. Baron S, Coppenhaver DH, Dianzani F, Fleischmann WR, Hughes TK, Klimpel GR, Niesel DW, Stanton GJ, Tyring SK. Interferon-Principles and medical applications. 1992;215-224 UTMB Press, Galveston.
16. Roers A, Hochkeppel H, Horisberger M, Haller AHA, Haller O. MxA gene expression after live virus vaccination: a sensitive marker for endogenous type I interferon. J Infect Dis. 169:1994;807-813.
17. Asada-Kubota M, Ueda T, Shimada M, Takeda K, Sokawa Y. Distribution of immunoreactive 2′,5′-oligoadenylate synthetase in mouse digestive tract. J Interferon Cytokine Res. 15:1995;863-867.
18. Bocci V. Roles of interferon produced in physiological conditions. A speculative review. Immunology. 64:1988;1-9.
19. Galabru J, Robert N, Buffet-Janvresse C, Riviere Y, Hovanessian AG. Continuous production of interferon in normal mice: effect of anti-interferon globulin, sex, age, strain and environment on the levels of 2-5A synthetase and p67K kinase. J Gen Virol. 66:1985;711-718.
20. Flenniken AM, Galabru J, Rutherford MN, Hovanessian AG, Williams BR. Expression of interferon-induced genes in different tissues of mice. J Virol. 62:1988;3077-3083.
21. Aebi M, Fah J, Hurt N, Samuel CE, Thomis D, Bazzigher J, Pavlovic J, Haller O, Staeheli P. cDNA structures and regulation of two interferon-induced human Mx proteins. Mol Cellular Biol. 9:1989;5062-5072.
22. Brandtzaeg P. Overview of the mucosal immune system. Curr Topics Microbiol Immunol. 146:1989;13-28.
23. Witmer MD, Steinman RM. The anatomy of peripheral lymphoid organs with emphasis on accessory cells: light-microscopy immuno-cytochemical studies of the mouse spleen, lymph node and Peyer's patch. Am J Ant. 170:1984;465-481.
24. Ermak T, Steger H, Pappo J. Phenotypically distinct subpopulations of T cells in domes and M-cell pockets of gut-associated lymphoid tissue. Immunology. 71:1990;530-537.
25. MacDonald TT. Immunosuppression caused by antigen feeding. II. Suppressor T cells mask Peyer's patches B cell priming to orally administered antigen. Eur J Immunol. 13:1983;138-142.
26. Mattingly JA. Immunologic suppression after oral administration of antigen. Cell Immunol. 86:1984;45-52.
27. Santos LMB, al-Sabbagh A, Londono A, Weiner HL. Oral tolerance to MBP induces TGF-β secreting T cell in Peyer's patch. J Immunol. 150:1993.
28. Streuli, M, Hall, A, Boll, W, Stewart, WE, Nagat, S, Weissman, C, Target cell specificity of two species of human interferon-α produced from Escherichia coli and of hybrid molecules derived from them, Proc Natl Acad Sci USA, 78, 2848, 2852.
29. Stanton G, Hughes T, Heard H, Georgiades J, Whorton E. Modulation of a natural virus defense system by low concentration of interferons at mucosal surfaces. J Interferon Res. 10:1990;S99.
30. Cummins JM, Tompkins MB, Olsen RG, Tompkins WA, Lewis MG. Oral use of human alpha interferon in cats. J Biol Response Modifiers. 7:1988;513-523.
31. Young AS, Cummins JM. The history of interferon and its use in animal therapy. E African Med J. 67:1990;SS31-63.
32. Lecce JG, Cummins JM, Richards AB. Treatment of rotavirus infection in neonate and weanling pigs using natural human interferon alpha. J Mol Biotherapy. 2:1990;211-216.
33. Kaiser G, Jaeger H, Birkmann J, Poppinger J, Cummins J, Gallmeier W. Low-dose oral natural human interferon-alpha in 29 patients with HIV-1 infection: a double-blind, randomized, placebo-controlled trial. AIDS. 6:1992;563-569.
34. Pfeffer LM, Donner DD. The downregulation of IFN-αreceptors in human lymphoblastoid cells: relation of cellular responsiveness to antiproliferative action of IFN-α Cancer Research. 50:1990;2654-2657.
35. Cantell K, Pyhala L. Circulating interferon in rabbits after administration by different routes. J Gen Virol. 20:1973;97-104.
36. Bocci V. Immunomodulators as local hormones: new insights regarding their clinical utilization. J Biol Res Mod. 4:1985;340-352.
37. Fleischmann WR, Koren S, Fleischmann CM. Oral administered interferons exert their white cell suppressive effects via a novel mechanism. Proc Soc Exp Biol Med. 201:1992;199-207.
38. Gibson DM, Cotler S, Spiegel HE, Colburn WA. Pharmacokinetics of recombinant leucocyte A interferon following various routes and modes of administration to the dog. J Interferon Res. 5:1985;403-408.
39. Wills RJ, Spiegel HE, Soike KF. Pharmacokinetics of recombinant leucocyte A interferon following IV infusion and bolus, IM, and PO administration to african green monkeys. J Interferon Res. 4:1984;399-409.
40. Radwanski E, Perentesis G, Jacobs S, Oden E, Affrime M, Symchowicz S, Zampaglione N. Pharmacokinetics of interferon α-2b in healthy volunteers. J Clin Pharmacol. 27:1987;432-435.
41. Brod, S, Kerman, R, Nelson, L, Marshall, GD, Henninger, EM, Khan, M, Jin, R, Wolinsky, JS, 1997, Ingested IFN-α has biological effects in humans, Mult Scler Clin Lab Res, 3, 1, 7.
42. Goldstein D, Sielaff KM, Storer BE, Brown RR, Datta SP, Witt PJ, Teitlebaum AP, Smalley RV, Borden EC. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-β serine. J Natl Cancer Inst. 81:1989;1061-1068.
43. Pfeffer LM, Colamonici OR. Transmembrane signalling by interferon-α Pharmac Ther. 52:1991;149-151.
44. Bocci V. Absorption of cytokines via the oropharyngeal associated lymphoid tissues - Does an unorthodox route improve the therapeutic index of interferon. J Clin Pharmacokinet. 21:1991;411-417.
45. Ford W, Gowan J. The traffic of lymphocytes. Semin Hematol. 6:1969;67-83.
46. Blalock JE, Baron S. Interferon induced transfer of viral resistance between animal cells. Nature. 269:1977;422-425.
47. Butcher EC. The regulation of lymphocyte traffic. Curr Topics Microbiol Immunol. 128:1986;85-122.
48. Butcher E, Picker L. Lymphocyte homing and homeostasis. Science. 272:1996;60-66.
49. ser. J Interferon Res. 9:1989;S51-60.